Notable
Praliciguat · Focal Segmental Glomerulosclerosis (FSGS)
Primary endpoint(s) modified
Also in this update: Trial sites expanded: 25 → 30 locations; Interventions modified
Akebia TherapeuticsPhase 2 NCT07268638 Registry history of NCT07268638 on ClinicalTrials.gov (opens the registry)